Italian pharmaceutical company Zambon - through its Swiss subsidiary Zambon Biotech SA - has entered into an exclusive licensing agreement with U.S. multinational Amneal Pharmaceuticals for an anti-Parkinson's drug. As of today, the drug, abbreviated as IPX203, is under review by the U.S. Food and Drug Administration, and Zambon - founded in Italy in 1906 and still run by the founder's family - will begin the process for regulatory approval and marketing in Europe. It is the extended-release version of the historic Parkinson's disease drug, levodopa.
|